 A double-blind, placebo-controlled study that aims to investigate the effect of 2-week and 12-week administration of USP methylene blue MB on cerebral blood flow, functional connectivity, memory and attention cognitive abilities using fMRI and behavioral measures in healthy aging, mild cognitive impairment MCI and mild Alzheimers disease AD subjects. 